| scholarly article | Q13442814 |
| P2093 | author name string | Claire Cook | |
| Tom Meade | |||
| Jackie Cooper | |||
| Riaz Zuhrie | |||
| P2860 | cites work | MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party | Q24541570 |
| Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421 | Q24805756 | ||
| Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease | Q28139910 | ||
| Final report on the aspirin component of the ongoing Physicians' Health Study | Q29619461 | ||
| Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group | Q29619877 | ||
| Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies | Q34469221 | ||
| Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease | Q34687253 | ||
| Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients | Q42556657 | ||
| Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors | Q48434703 | ||
| Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial) | Q52397402 | ||
| A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators | Q66890716 | ||
| Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party | Q67588661 | ||
| A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants | Q67939868 | ||
| Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration | Q72267713 | ||
| Fibrinogen after coronary angioplasty as a risk factor for restenosis | Q72331374 | ||
| Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS) | Q72841203 | ||
| Implication of fibrate therapy for homocysteine | Q73064926 | ||
| Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study | Q73715603 | ||
| Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Res | Q74147342 | ||
| P433 | issue | 7373 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | randomized controlled trial | Q1436668 |
| P304 | page(s) | 1139 | |
| P577 | publication date | 2002-11-01 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Bezafibrate in men with lower extremity arterial disease: randomised controlled trial | |
| P478 | volume | 325 |
| Q41501265 | "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study |
| Q57621177 | 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) |
| Q31101617 | All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. |
| Q24235178 | Antiplatelet agents for intermittent claudication |
| Q90145015 | Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials |
| Q28200554 | Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins |
| Q37770113 | Atherosclerosis, diabetes and lipoproteins |
| Q47801721 | Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong |
| Q36411656 | Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? |
| Q35809770 | Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies |
| Q37030666 | Cholesterol trials and mortality |
| Q28728567 | Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy |
| Q73754671 | Does sticky blood predict a sticky end? Associations of blood viscosity, haematocrit and fibrinogen with mortality in the West of Scotland |
| Q24816834 | Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons |
| Q28205109 | Dyslipidaemia |
| Q38777322 | Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease |
| Q90219731 | Dyslipidemia Profiles in Patients with Peripheral Artery Disease |
| Q35693903 | Dyslipoproteinemia and peripheral arterial occlusive disease |
| Q44783407 | Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease |
| Q28244205 | Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients |
| Q33576435 | Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. |
| Q58612883 | Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases |
| Q28195408 | Emerging drugs in peripheral arterial disease |
| Q90722135 | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence |
| Q24815913 | Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] |
| Q44502945 | Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. |
| Q28220294 | Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review |
| Q37576105 | Fibrate therapy and renal function |
| Q44922813 | Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients |
| Q94454408 | Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction |
| Q36679599 | Fibrates after the FIELD study: Some answers, more questions |
| Q21246041 | Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction |
| Q30241199 | Fibrates for primary prevention of cardiovascular disease events. |
| Q24186376 | Fibrates for secondary prevention of cardiovascular disease and stroke |
| Q35602779 | Fibrates for treatment of the metabolic syndrome |
| Q49571281 | Fibrates in the management of atherogenic dyslipidemia. |
| Q43029247 | Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going? |
| Q30422549 | LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality? |
| Q37810593 | Lipid lowering for secondary prevention of cardiovascular disease in older adults |
| Q34530349 | Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention |
| Q24243312 | Lipid-lowering for peripheral arterial disease of the lower limb |
| Q90321036 | Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence |
| Q38039980 | Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. |
| Q21144649 | Mendelian randomisation and causal inference in observational epidemiology |
| Q37429025 | New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people? |
| Q33984026 | Novel markers of peripheral arterial disease |
| Q38074335 | Novel strategies for managing dyslipidemia: treatment beyond statins |
| Q37367669 | Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy |
| Q37130100 | PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders |
| Q34451668 | Peripheral arterial disease: a literature review. |
| Q28220999 | Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease |
| Q37494202 | Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review |
| Q46486524 | Risk modification in patients with peripheral arterial disease: a retrospective survey |
| Q35904825 | Role of fibric acid derivatives in the management of risk factors for coronary heart disease |
| Q34041102 | Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials |
| Q24245521 | Statins and fibrates for preventing melanoma |
| Q34042836 | The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies |
| Q24804541 | The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481] |
| Q34730815 | The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer |
| Q95492629 | The use of fibric Acid derivatives in cardiovascular prevention |
| Q28219591 | Therapy insight: peripheral arterial disease and diabetes--from pathogenesis to treatment guidelines |
| Q36560981 | Treatment of hypertriglyceridemia |
| Q36766923 | Update on the use of fibrates: focus on bezafibrate |
| Q34428524 | Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials |
| Q26765234 | Use of fibrates in the metabolic syndrome: A review |
| Q24804259 | Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? |
| Q82061599 | [The role of statins in atherosclerotic peripheral arterial disease] |
| Q22066036 | ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?* |
Search more.